Gilead Sciences Inc News - GILD

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

– Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

– Long-Term Analysis Shows Similar Safety and Effectiveness Outcomes in Outpatient vs. Inpatient Setting with Positive Impact for Healthcare...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

– First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L...

Form 144 - Report of proposed sale of securities

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

– Second Positive Phase 3 Trial in First-line Metastatic TNBC Where Trodelvy Has Demonstrated a Clinically Meaningful Benefit Versus Standard of...

jondoeuk 16 hours ago

They are moving beyond quadruple edited to build a sextuple-edited CAR-T therapy for glioblastoma.

👍️0

TucsonPhil 3 days ago

https://www.cnbc.com/2025/06/18/fda-approves-gilead-hiv-prevention-injection-lenacapavir.html

This should be great news, but from a financial, shareholder perspective, there are concerns about cost and availability, with U.S. government programs cutting funding for HIV prevention programs.

👍️0

jondoeuk 4 days ago

I've heard that an MD Anderson team is developing an off-the-shelf IL-21 armoured CAR-NK cell therapy that will target EGFR and IL13Ra2 https://www.cell.com/cancer-cell/abstract/S1535-6108(24)00272-1

They are also testing another off-the-shelf NK cell therapy with containing deleted of TGFBR2 and NR3C1 in recurrent glioblastoma. This makes the NKs resistant to tumour- and corticosteroid-induced immunosuppression, respectively. Going forward, they plan to test these NKs with Delta-24-RGD https://ascopubs.org/doi/10.1200/JCO.2017.75.8219

When combined with NKs, they found that treatment with Delta-24-RGD altered the immunosuppressive tumour microenvironment and increased the recruitment, antitumour activity, survival, and memory of endogenous NKs as well.

👍️0

jondoeuk 5 days ago

It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to the KITE-363 benchmark.

Also, KITE-753 exhibited enhanced cytokine production, enhanced proliferation, increased peripheral peak expansion, and superior antitumour efficacy compared to the KITE-363 benchmark.

* CCR7+/CD45RA+CD4+ of ~60% vs ~5%, and CCR7+/CD45RA+CD8+ of ~80% vs ~15%. High circulating CCR7+ populations positively correlate with antitumour response https://www.nature.com/articles/s41591-020-1061-7

👍️0

jondoeuk 5 days ago

Others https://www.oncologypipeline.com/apexonco/lyell-takes-jj-and-gilead

👍️0

jondoeuk 5 days ago

An update https://www.oncologypipeline.com/apexonco/eha-2025-arcellx-still-hopes-safety-will-trump-efficacy

👍️0

jondoeuk 1 week ago

The UPenn team have been developing this https://jitc.bmj.com/content/11/Suppl_1/A323

👍️0

jondoeuk 2 weeks ago

One company is developing an off-the-shelf version https://www.kiragenbio.com/our-science

👍️0

jondoeuk 3 weeks ago

ASCO: Kite's CAR-T passes lymphoma safety trial with flying colors https://www.fiercebiotech.com/biotech/asco-kites-car-t-passes-lymphoma-safety-trial-flying-colors

👍️0

jondoeuk 3 weeks ago

Dual-target CAR T cell therapy slows growth of aggressive brain cancer https://medicalxpress.com/news/2025-05-dual-car-cell-therapy-growth.html

👍️0

BottomBounce 1 month ago

Dr. Paul Marik:

Hospital Would not allow me to Use Vitamin C, but wanted me to Use Remdesivir, Which Increases risk of Kidney Failure by 20X & increases Death by 4%

The Federal Government will give Hospitals 20% Bonus if you prescribe Remdesivir pic.twitter.com/Rk0F024jBf— Asher Press (@AsherPress) June 19, 2024 $GILD

👍️0

fink 2 months ago

Yulp.
New Management style = Company first lay offs.
AIDS is cured.
HepC is cured
Cancer is a nothing burger but a management waste of money
All they got is Prep.

I'm thinking a golden opportunity to short this top heavy pig. They got nothing in the pipeline but cost cutting.

👍️0

Greedy G 4 months ago

~sold the 2/14 $108 calls @.20c

👍️0

Greedy G 4 months ago

~bought the 2/14 $108 calls @.05c ahead of earnings today

👍️0

fink 5 months ago

Looks like the National Sales meeting in Vegas, has employees dumping after this high.
Management must not be painting much hope for the future.

I can't wait to hear what the pump is to keep employees from bailing out.

👍️0

jondoeuk 7 months ago

They now add an investigational HIV vaccine to its portfolio https://www.fiercebiotech.com/biotech/gilead-buys-hiv-vaccine-spanish-biotech-following-success-clinical-collab

Data on the vaccine in combination with vesatolimod https://www.ddw-online.com/hiv-combination-regimen-could-lead-to-viral-remission-22215-202302/

👍️0

jondoeuk 7 months ago

Based on recent data*, I would have thought that getting KITE-509 into the clinic (for GPC3+ solid tumours, not just 3L+ HCC) would be a priority.

* https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019 https://www.nature.com/articles/s41586-024-08261-8

👍️0

fink 7 months ago

CEO is talking now.
The stock is selling off on great words.
Go figure! 6month Prep shot is a game changer. Generics are already being made for third world nations. These guys are going to eradicate AIDS.

They should be allowed to make a buck or two.
I want $250 a share please, I've held it way too long.

👍️0

Monksdream 8 months ago

GILD, 10Q 11/6

👍️0

Monksdream 8 months ago

GILD a new 52 week high

👍️0

Monksdream 8 months ago

GILD new 52=week high

👍️0

jondoeuk 8 months ago

Two years later, and here are some of my takeaways...

- They know they need to expand into more (rural) areas and that might include pre-built clean rooms. Slides 21-26 show how difficult it is to drive uptake further. "Majority of future growth expected from establishing new ATC's in community." These centres need to establish new relationships with others for apheresis, local ER's for (CRS/ICANS) emergencies and even local freezer storage requirements, which is it's own thing. So much goes into treatment that has nothing to do with manufacturing.

- Forgot ZUMA-12 data was that good. A 86% CR rate and 81% three-year survival from 1L patients. Not sure how to compare that to later line trials, but decades from now, let's hope we are at the point we treat this front line (vs SOC now). Kite said their COGS is

👍️0

jondoeuk 8 months ago

''There have been more than 250 HIV vaccine trials, most of them early-stage, looking at whether the vaccine is safe and whether we mount an immune response following vaccination. There have been very few vaccine trials—10 or so—that have advanced to the point of looking at efficacy. Of those, one showed 31% efficacy at 42 months. That was the most promising trial, but the efficacy fell off very quickly, and it was only 31% and only against clade B. Whether that would translate to the other clades is not clear.'' https://publichealth.jhu.edu/2022/why-dont-we-have-an-hiv-vaccine

👍️0

jondoeuk 8 months ago

How the hell is Dan O'Day still making 26 mil? A monkey throwing dart would have been better than this dimwit— Jack Shaw (@JackSha90859576) October 19, 2024

👍️0

TechandBio 9 months ago

Wants to go higher!

$GILD

👍️0

Monksdream 9 months ago

GILD approaching a 52 week high

👍️0

north40000 9 months ago

Featured on CNBC-TV this morning, 8:40 a.m. time frame.

👍️0

TechandBio 11 months ago

NICE!

clutch stock with a disruptive cure prevention vaccine for HIV people would rather take 2 shots a year not to get HIV then taking oral pills for treatment!

$GILD

👍️0

TechandBio 11 months ago

Adding shares and calls under $80..00

HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.

$GILD
$GILD

👍️0

midastouch017 11 months ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

FDA clearance triggers a $30 million milestone payment from Gilead

👍️0

Monksdream 11 months ago

GILD under $100

👍️0

TechandBio 11 months ago

Target is $100-$120 by Q2 2025

$GILD

👍️0

TechandBio 11 months ago

HIV Prevention CURE Shot 2x a year

Great growing oncology pipeline!

my $80 vertical Calls from last week are looking golden!

$GILD

👍️0

north40000 1 year ago

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

"Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"

👍️0

north40000 1 year ago

How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.

👍️0

jondoeuk 1 year ago

There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.

👍️0

jondoeuk 1 year ago

A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems

👍️0

jondoeuk 1 year ago

They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study

👍️0

jondoeuk 1 year ago

''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html

👍️0

jondoeuk 1 year ago

The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.

👍️0

jondoeuk 1 year ago

The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution

👍️0

jondoeuk 1 year ago

IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve

👍️0

jondoeuk 1 year ago

Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.

👍️0

jondoeuk 1 year ago

Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf

👍️0

jondoeuk 1 year ago

I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and

👍️0

jondoeuk 1 year ago

Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568

👍️0

Monksdream 1 year ago

GILD new 52 week high

👍️0

jondoeuk 2 years ago

Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.

👍️0

jondoeuk 2 years ago

Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them

👍️0

jondoeuk 2 years ago

The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Gilead Sciences Inc (GILD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GILD News

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Form 144 - Report of proposed sale of securities

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

GILD Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Gilead Sciences Inc (GILD) News

Gilead Sciences Inc (GILD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GILD News

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Form 144 - Report of proposed sale of securities

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

GILD Discussion

Your Recent History

Company

Business

Popular

Get The App

Sign in

Go Ad-Free